Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAI3 | P08754 | 1/20 | 0.50 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.50 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.50 |
| ▸ | ARG1 | P05089 | 1/20 | 0.40 |
| ▸ | ARG2 | P78540 | 1/20 | 0.40 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.33 |
| ▸ | CCR5 | P51681 | 1/20 | 0.33 |
| ▸ | HRH2 | P25021 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL856924 | 0.98 | GNAI3 (0.53) | GNAI3GNAO1GNAI1ARG1ARG2 | |
| SCHEMBL18575434 | 0.89 | GNAI3 (0.40) | GNAI3GNAO1GNAI1ARG1ARG2 | |
| SCHEMBL4144334 | 0.88 | GNAI3 (0.56) | GNAI3GNAO1GNAI1ARG1ARG2 | |
| SCHEMBL20648687 | 0.86 | GNAI3 (0.59) | GNAI3GNAO1GNAI1ARG1ARG2 | |
| SCHEMBL13519612 | 0.84 | ARG1 (0.38) | GNAI3GNAO1GNAI1ARG1ARG2 | |
| SCHEMBL25036354 | 0.84 | GNAO1 (0.62) | GNAI3GNAO1GNAI1ARG1ARG2 | |
| SCHEMBL22415214 | 0.82 | GNAI3 (0.50) | GNAI3GNAO1GNAI1ARG1ARG2 | |
| SCHEMBL20648690 | 0.81 | GNAI3 (0.46) | GNAI3GNAO1GNAI1SPHK1SIGMAR1 | |
| SCHEMBL8085877 | 0.80 | CARM1 (0.52) | SIGMAR1HRH3CARM1PRMT6PRMT1 | |
| SCHEMBL9974271 | 0.78 | ARG1 (0.35) | ARG1ARG2NOS3NOS1NOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370779-B2 | Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer | Pelemed Co., Ltd. (KR) | 2022-06-28 | — | — | US | disclosed |
| US-20200270229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ACUTE MYELOID LEUKEMIA OR METASTATIC BREAST CANCER | Pelemed Co., Ltd. (KR) | 2020-08-27 | — | — | US | disclosed |
| CN-102414168-B | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD | 2014-05-21 | — | — | CN | disclosed |
| US-8563714-B2 | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-10-22 | — | — | US | disclosed |
| EP-2432760-B1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2013-07-17 | — | — | EP | disclosed |
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-05-10 | — | — | US | disclosed |
| CN-102414168-A | Bridged spiro [2.4] heptane derivatives as ALX receptor and/or FPRL2 agonists | ACTELION PHARMACEUTICALS LTD | 2012-04-11 | — | — | CN | disclosed |
| EP-2432760-A1 | BRIDGED SPIRO [2.4]HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010134014-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-11-25 | — | — | WO | disclosed |
| US-20080076762-A1 | Novel 4-Aminopiperidine Derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2008-03-27 | — | — | US | disclosed |
| WO-2006056930-A2 | NOVEL 4 -AMINOPIPERIDINE DERIVATIVES AS PLASMEPSIN II INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-06-01 | — | — | WO | disclosed |
| US-4153702-A | Basically alkylated dithiosalicyclic acid amides and their use as medicaments | BAYER AKTIENGESELLSCHAFT (DE) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115841-A1 | BRIDGED SPIRO [2.4] HEPTANE DERIVATIVES AS ALX RECEPTOR AND/OR FPRL2 AGONISTS | FPR1, FPR2, FPR3 | GNAI3 1672/4885GNAO1 592/4885GNAI1 1334/4885 |
| US-20200270229-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ACUTE MYELOID LEUKEMIA OR METASTATIC BREAST CANCER | FLT3, ABL1, MCL1 | GNAI3 1147/4885GNAO1 3884/4885GNAI1 1237/4885 |
| US-20080076762-A1 | Novel 4-Aminopiperidine Derivatives | METAP1, DNPEP, PEPD | GNAI3 3721/4885GNAO1 2893/4885GNAI1 2247/4885 |
| US-11370779-B2 | Pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer | FLT3, ABL1, MCL1 | GNAI3 1147/4885GNAO1 3884/4885GNAI1 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.